Meet Sarah, a 55-year-old Businesswoman With Multiple Myeloma Considering CAR-T Therapy With Ide-cel

Now Viewing

EP: 1.Meet Sarah, a 55-year-old Businesswoman With Multiple Myeloma Considering CAR-T Therapy With Ide-cel

EP: 2.Managing Adverse Events with CAR T-Cell Therapy: Best Practices for Myeloma Care Teams

EP: 3.Managing Neurotoxicities in CAR T: Clinical Approaches and Patient/Caregiver Education

EP: 4.QOL Considerations for Optimal Patient Outcomes with CAR-T Therapy

EP: 5.Getting to Know Robert, a 72-Year-Old Retired Teacher Facing a Myeloma Relapse and Considering CAR-T Therapy with Cilta-cel

EP: 6.Long-Term CAR-T Management in Myeloma: Collaborative Care and Monitoring Strategies for Patients Like Robert

EP: 7.Life After CAR T Therapy: Insights for Patients and Referring Oncologists

Video content above is prompted by the following:

• 55-year-old female, CEO of tech startup, diagnosed with multiple myeloma 5 years ago
• Initial treatment: 4 cycles DVRd, followed by ASCT and maintenance therapy
• Relapsed after 18 months and received KPd, but stopped after neurotoxicity and cardiac toxicity
• Otherwise healthy, active lifestyle, strong support system
• Receives ide-cel